Molecular and biological properties of an abrin A chain immunotoxin designed for therapy of human small cell lung cancer.

  title={Molecular and biological properties of an abrin A chain immunotoxin designed for therapy of human small cell lung cancer.},
  author={Edward J. Wawrzynczak and Uwe Zangemeister‐Wittke and Robert J Waibel and Raymond V. Henry and Geoffrey D. Parnell and Alan J. Cumber and M. Jones and Rolf Stahel},
  journal={British Journal of Cancer},
  pages={361 - 366}
An immunotoxin (IT) comprising abrin A chain attached to the mouse monoclonal antibody SWA11, recognising a cell surface antigen highly associated with human small cell lung cancer (SCLC), was synthesised using a hindered disulphide crosslinker, N-succinimidyl 3-(2-pyridyldithio) butyrate (SPDB), and purified by Blue Sepharose CL-6B affinity chromatography. The IT preparation contained monomeric conjugate, composed of one abrin A chain molecule linked to one SWA11 molecule, and was free from… 
Anti‐tumor activity of a blocked ricin immunotoxin with specificity against the cluster‐5A antigen associated with human small‐cell lung cancer
The monoclonal antibody SEN3I, a mouse IgG1 which recognizes the cluster‐5a antigen on small‐cell lung cancer (SCLC) cells, was used to prepare a selective and potent blocked ricin immunotoxin, which was potently and selectively active against SCLC cell lines both of classic and of variant morphologies.
Refinement of an indirect immunotoxin assay of monoclonal antibodies recognising the human small cell lung cancer cluster 2 antigen.
MOC-31-ricin A chain selectivity inhibited the incorporation of [3H]leucine by the NCI-H69, SW2 and GLC-8 SCLC cell lines, but exerted no selective toxic effects upon human lung and non-lung tumour cell lines lacking surface expression of the cluster 2 antigen.
Growth suppression of human colorectal carcinoma in nude mice by monoclonal antibody C27-abrin A chain conjugate
Results indicate that MAAC may be of benefit in therapy during or soon after resection of colorectal carcinoma or in patients who have micrometastasis.
The selective cytotoxicity of cobra venom factor immunoconjugate on cultured human nasopharyngeal carcinoma cell line
Results indicate that the CVF immunoconjugate has complement-mediated selective cytotoxicity on CNE2 cells, which can be potentiated by DLF.
Exploring Cytotoxic mRNAs as a Novel Class of Anti-cancer Biotherapeutics
Immunotoxins as cancer chemotherapeutic agents
The finding that rats serve as a model to study BR96 sFv‐PE40 mediated VLS has led to identification of potential inhibitors of this dose‐limiting toxicity, and immunotoxins, especially single‐chain forms, offer exciting possibilities for therapy of cancer.
Action of a cd24‐specific deglycosylated ricin‐a‐chain immunotoxin in conventional and novel models of small‐cell‐lung‐cancer xenograft
The therapeutic efficacy of an immunotoxin, SWA II‐SPDB‐dg.ricin A chain, recognizing the leukocyte‐differentiation antigen CD24, was evaluated against SCLC cell lines in tissue culture and in 2 nude‐mouse models, finding that growth of the solid tumors after the initial response and the clonogenic activity in the sponge‐derived cell population were mediated by CD24‐positive cells.
Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Various strategies that can increase the efficacy and lower the required dose for targeted toxins have been compiled in this article, which shows that with the advancements in platform technologies or improved endosomal escape the usage of tumor targeted RIPs would see the daylight of clinical success.


Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen.
The potential of mouse monoclonal antibodies for recognising different antigens associated with human small cell lung cancer (SCLC) to form active immunotoxins was assessed by an indirect in vitro
Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants.
The A-chain of the plant toxin abrin was covalently linked to monoclonal anti-Thy 1.1 antibody (OX7) with the use of either N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) or 2-iminothiolane
Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin.
Fib75-abrin A chain was found to be about 3- to 4-fold more resistant than the other immunotoxins to breakdown by reduction of the disulfide linkage between the A chain and the antibody with glutathione in vitro, which suggests that the longer serum half-life of Fib75-abs Rin A chain may have been due to greater stability against reduction in vivo.
Delivery of ricin and abrin A-chains to human carcinoma cells in culture following covalent linkage to monoclonal antibody LICR-LOND-Fib 75.
These covalent conjugates, particularly the one containing abrin A-chain, may find application in freeing human bone marrow ex vivo of infiltrated tumor cells prior to reinfusion as an autograft.
Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A chain conjugates.
In vivo experiments showed that gelonin conjugates are not toxic up to 2 mg total dose/mouse and significantly retarded the growth of established s.c. tumor.
Comparative biochemical, cytotoxic and pharmacokinetic properties of immunotoxins made with native ricin a chain, ricin A1 chain and recombinant ricin a chain
The β‐phase half‐lives of fib75‐recombinant ricin A chain and Fib75‐ricin A, chain were similar, consistent with the identical susceptibility of the immunotoxins to cleavage by glutathione, as well as the presence of the complex‐type oligosaccharide side‐chain on the A1 chain, which may have accelerated the clearance of the A2 chain immunotoxin.
Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
Both the use of the SMPT cross-linker and deglycosylation of the A-chain significantly improve the therapeutic index of the immunotoxins in AKR-A/2 tumor-bearing mice.
Selective antitumor effect on L10 hepatocarcinoma cells of a potent immunoconjugate composed of the A chain of abrin and a monoclonal antibody to a hepatoma-associated antigen.
In vivo studies showed that the conjugate was not toxic at a dosage of 60 to 1120 micrograms/guinea pig, the conjUGate decreased or abolished the growth of established solid tumors, the Conjugate delayed or inhibited tumor metastases to lymph nodes, and 20 to 40% of the animals in selective groups had a long-term complete regression.